How should co-amoxiclav (amoxicillin + clavulanic acid) 1.2 g be administered intravenously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intravenous Administration of Co-Amoxiclav 1.2g

Co-amoxiclav 1.2g (1000mg amoxicillin + 200mg clavulanic acid) should be administered intravenously by slow injection over 3-4 minutes or by intravenous infusion over 30-40 minutes, given every 8 hours. 1, 2

Preparation and Administration Method

For IV Injection (Bolus):

  • Reconstitute the 1.2g vial with 20mL of sterile water for injection
  • Administer slowly over 3-4 minutes directly into a vein or via the tubing of an existing IV line
  • This method is suitable for immediate administration

For IV Infusion:

  • Reconstitute the 1.2g vial with a compatible diluent (0.9% sodium chloride, water for injection, or Ringer's solution)
  • Add to 50-100mL of compatible IV fluid
  • Infuse over 30-40 minutes
  • This is the preferred method for hospitalized patients requiring multiple doses 1, 3, 4

Dosing Frequency and Duration

The standard regimen is 1.2g every 8 hours (three times daily) 1, 2, 3, 4. This dosing interval is critical because:

  • Both amoxicillin and clavulanic acid have relatively short half-lives (approximately 1-1.4 hours) 5
  • Time-dependent killing requires maintaining concentrations above the MIC for optimal bacterial eradication
  • Eight-hourly dosing ensures adequate tissue penetration, with bronchial mucosal concentrations reaching 200% of serum levels for amoxicillin 6

Step-Down Therapy Approach

For severe infections, use a sequential IV-to-oral approach:

  • Start with 1.2g IV every 8 hours for 2-4 days
  • Switch to oral co-amoxiclav 625mg (500mg/125mg) three times daily once clinically improving
  • This step-down approach has demonstrated 95% efficacy in respiratory tract infections 3, 7

The transition to oral therapy is appropriate when the patient is:

  • Afebrile for 24-48 hours
  • Hemodynamically stable
  • Able to tolerate oral medications
  • Showing clinical improvement

Stability and Preparation Considerations

Critical stability limitations:

  • Once reconstituted, use immediately or within 20 minutes at room temperature 8
  • If refrigerated at 4°C, amoxicillin retains 90% potency for 7.8-10 hours, but clavulanic acid is less stable 8
  • Do not prepare solutions in advance for later use - the poor stability of clavulanic acid at room temperature (only 5.9-8.8 hours at ambient temperature) makes this impractical 8
  • For prolonged infusions beyond 4 hours, consider preparing amoxicillin and clavulanic acid in separate containers, though this requires specialized protocols 9

Renal Dose Adjustments

For patients with impaired renal function:

  • GFR 10-30 mL/min: 1.2g every 12 hours
  • GFR <10 mL/min: 1.2g every 24 hours
  • Hemodialysis patients: 1.2g every 24 hours, with an additional dose during and after dialysis 10

Common Pitfalls to Avoid

  1. Do not administer as a rapid IV push - this increases risk of thrombophlebitis and patient discomfort. Always give over at least 3-4 minutes 1

  2. Do not mix with blood products or protein-containing solutions - co-amoxiclav is incompatible with these fluids

  3. Do not assume oral and IV formulations are interchangeable in timing - the 1.2g IV dose every 8 hours is NOT equivalent to 625mg oral every 8 hours; oral dosing requires higher amoxicillin content due to first-pass metabolism

  4. Avoid using first-generation cephalosporins as alternatives - these are ineffective for the same indications and should not be substituted 11

  5. Monitor for hypersensitivity - while cross-reactivity between penicillins and cephalosporins is lower than historically reported (likely <2% rather than 10%), true penicillin allergy remains a contraindication 12

The IV route is specifically indicated for severe infections including hospital-acquired pneumonia, complicated intra-abdominal infections, severe skin and soft tissue infections, and when oral administration is not feasible 1, 2, 13.

References

Research

[Amoxycillin/potassium clavulanate in inpatients with bronchopulmonary infections].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.